

EFFECTIVE DATE: 11 | 10 | 2016

POLICY LAST UPDATED: 09 | 20 | 2016

OVERVIEW

This policy describes the coverage of molecular testing for the indications of pancreatic cyst/mass where diagnostic evaluations are inconclusive.

MEDICAL CRITERIA

BlueCHiP for Medicare

The specific requirements for medical necessity involve:

1. Highly-concise affirmation, documented in the medical record, that a decision regarding treatment has not already been made and that the results of the molecular evaluation will assist in determining if more aggressive treatment than what is being considered is necessary.
2. Previous first-line diagnostics, such as, but not restricted to, the following have demonstrated:
 - a. A pancreatic cyst fluid carcinoembryonic antigen (CEA), which is greater than or equal to 200 ng/ml, suggesting a mucinous cyst, but is not diagnostic.
 - b. Cyst cytopathologic or radiographic findings, which raise the index of malignancy suspicion, but where second-line molecular diagnostics is expected to be more compelling in the context of a surgical vs. non-surgical care plan.

PRIOR AUTHORIZATION

BlueCHiP for Medicare

Prior authorization is required and is obtained via the online tool for participating providers. See the Related Policies section.

Commercial Products

Not applicable

POLICY STATEMENT

BlueCHiP for Medicare

PathfinderTG molecular testing is only medically necessary for pancreatic cyst/mass when the medical criteria are met.

All PathfinderTG® indications other than pancreatic cyst fluid evaluation are considered not medically necessary due to insufficient data on both analytical and clinical validity.

Note: BCBSRI must follow CMS (Centers for Medicare and Medicaid Services) guidelines, such as national coverage determinations or local coverage determinations for all BlueCHiP for Medicare policies. Therefore, BlueCHiP for Medicare policies may differ from Commercial Products. In some instances, benefits for BlueCHiP for Medicare may be greater than what is allowed by the CMS.

Commercial Products

Molecular testing using the PathFinderTG system is considered **not medically necessary** for all indications including the evaluation of pancreatic cyst fluid and of suspected or known gliomas, and Barrett esophagus as there is inadequate peer reviewed data to support its use.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for limitations of benefits/coverage when services are not medically necessary.

BACKGROUND

Commercial

Topographic genotyping, also called molecular anatomic pathology, integrates microscopic analysis (anatomic pathology) with molecular tissue analysis. Under microscopic examination of tissue and other specimens, areas of interest may be identified and microdissected to increase tumor cell yield for subsequent molecular analysis. Topographic genotyping may permit pathologic diagnosis when first-line analyses are inconclusive.

RedPath Integrated Pathology (now Interpace Diagnostics) has patented a proprietary platform called PathFinderTG; it provides mutational analyses of patient specimens. The patented technology permits analysis of tissue specimens of any size, “including minute needle biopsy specimens,” and any age, “including those stored in paraffin for over 30 years.” Interpace currently describes PathFinderTG test called PancaGEN on its website and describes another PathFinder test called BarreGEN™ as “in the pipeline”. As stated on the company website, PancaGEN integrates molecular analyses with first-line results (when these are inconclusive) and pathologist interpretation. The manufacturer calls this technique integrated molecular pathology. Test performance information is not provided on the website.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests (LDTs) must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Patented diagnostic tests (eg, PancaGEN™) are available only through Interpace Diagnostics (Pittsburgh, PA and New Haven, CT; formerly RedPath Integrated Pathology) under the auspices of CLIA. Laboratories that offer LDTs must be licensed by CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

For individuals who have pancreatic cysts who do not have a definitive diagnosis after first-line evaluation and who receive standard diagnostic and management practices plus topographic genotyping (PancaGEN molecular testing), the evidence includes retrospective studies of clinical validity and clinical utility. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, change in disease status, morbid events, and quality of life. The best evidence of incremental clinical validity comes from the National Pancreatic Cyst Registry report that compared PancaGEN performance characteristics to current international consensus guidelines and provided preliminary but inconclusive evidence of a small incremental benefit for PancaGEN. The analyses from the registry study included only a small proportion of enrolled patients, relatively short follow-up time for observing malignant transformation, and limited data on cases where the PancaGEN results are discordant with international consensus guidelines. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have Barrett esophagus who receive standard prognostic techniques plus topographic genotyping (BarreGEN molecular testing), the evidence includes 2 observational studies evaluating the performance characteristics of a panel of genetic markers in Barrett esophagus. Relevant outcomes are overall survival, disease-specific survival, test accuracy and validity, change in disease status, morbid events, and quality of life. The studies showed that high mutational load could distinguish less versus more severe histology and was a predictor of progression in Barrett esophagus. It is not clear if the test used was specifically BarreGEN or if the BarreGEN prognostic algorithm was applied for classification. The evidence is insufficient to determine the effects of the technology on health outcomes.

BlueCHiP for Medicare

PathfinderTG® will be considered medically reasonable and necessary when selectively used as an **occasional second-line diagnostic supplement**:

- only where there remains clinical uncertainty as to either the current malignancy or the possible malignant potential of the pancreatic cyst based upon a comprehensive first-line evaluation; **AND**
- a decision regarding treatment (e.g. surgery) has NOT already been made based on existing information.

DOCUMENTATION REQUIREMENTS

1. All documentation must be maintained in the patient's medical record and made available to the contractor upon request.
2. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service(s)). The documentation must include the legible signature of the physician or non-physician practitioner responsible for and providing the care to the patient.
3. The submitted medical record must support the use of the selected ICD-10-CM code(s). The submitted CPT/HCPCS code must describe the service performed.
4. The medical record documentation must support the medical necessity of the services as directed in this policy.
5. The medical record must clearly indicate the purpose of the Pathfinder TG® test.
6. The medical record should clearly support why and how the first-line diagnostic work-up was insufficient to adequately monitor or manage the pancreatic cyst(s) under evaluation, such that this very specialized second-line PathfinderTG®testing has become necessary.

CODING

BlueCHiP for Medicare and Commercial Products

There is no established CPT or HCPCS code which adequately describes the procedure; therefore, it may be reported using an unlisted CPT code (84999 or 81479)

RELATED POLICIES

Preauthorization via online tool for Genetic Testing

PUBLISHED

Provider Update, December 2016
 Provider Update, January 2016
 Provider Update, January 2015
 Provider Update, September 2013
 Provider Update, June 2012
 Provider Update, July 2011
 Provider Update, July 2010
 Provider Update, August 2009

REFERENCES

1. Trikalinos T, Terasawa T, Raman G. A systematic review of loss-of-heterozygosity based topographic genotyping with PathfinderTG®. AHRQ Technology Assessment Program 2010. Available online at: <http://www.cms.gov/determinationprocess/downloads/id68ta.pdf>. Last accessed April 2014.
2. U.S. Patent #7,014,999. Finkelstein et al. March 21, 2006. Topographic genotyping. [http://patft.uspto.gov/netacgi/nphParser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnethtml%2FPTO%2Fsearchadv.htm&r=16&f=G&l=50&d=PTXT&S1=\(redpath+AND+specimen\)&OS=redpath+AND+specimen&RS=\(redpath+AND+specimen\)](http://patft.uspto.gov/netacgi/nphParser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnethtml%2FPTO%2Fsearchadv.htm&r=16&f=G&l=50&d=PTXT&S1=(redpath+AND+specimen)&OS=redpath+AND+specimen&RS=(redpath+AND+specimen)). Accessed April 30, 2015
3. Interpace Diagnostics. Advancing patient care through molecular diagnostic testing. 2016; <http://www.interpacediagnostics.com/>. Accessed June 24, 2016.
4. Interpace Diagnostics. How PancaGEN works. 2016; <http://www.interpacediagnostics.com/pancagen/how-it-works/>. Accessed June 24, 2016.

- 5 Vege SS, Ziring B, Jain R, et al. American Gastroenterological Association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. *Gastroenterology*. Apr 2015;148(4):819-822; quiz 812-813. PMID 25805375
6. Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. *Am J Gastroenterol*. May 2015;110(5):662-682; quiz 683. PMID 25869390
7. Interpace Diagnostics. Clinical utility. 2016; <http://www.interpacediagnostics.com/pancragen/clinical-utility/>. Accessed June 29, 2016
8. RedPath Integrated Pathology. Services. ©2013. <http://redpathip.com/services/pathfindertg-pancreas>. Accessed April 30, 2015
8. Lapkus O, Gologan O, Liu Y et al. Determination of sequential mutation accumulation in pancreas and bile duct brushing cytology. *Mod Pathol* 2006; 19(7):907-13.
9. Khalid A, Pal R, Sasatomi E et al. Use of microsatellite marker loss of heterozygosity in accurate diagnosis of pancreaticobiliary malignancy from brush cytology samples. *Gut* 2004; 53(12-Jan):1860-5.
10. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. *Pancreatology*. May-Jun 2012;12(3):183-197. PMID 22687371
11. Al-Haddad MA, Kowalski T, Siddiqui A, et al. Integrated molecular pathology accurately determines the malignant potential of pancreatic cysts. *Endoscopy*. Feb 2015; 47(2):136-142. PMID 25314329
12. Gillis A, Cipollone I, Cousins G, et al. Does EUS-FNA molecular analysis carry additional value when compared to cytology in the diagnosis of pancreatic cystic neoplasm? A systematic review. *HPB (Oxford)*. May 2015; 17(5):377-386. PMID 25428782
13. Centers for Medicare and Medicaid Services (cms.gov) Local Coverage Determination (LCD): Loss-of-Heterozygosity Based Topographic Genotyping with PathfinderTG[®] (L34864) https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=34864&ver=23&CtrctrSelected=323*1&Ctrctr=323&s=45&DocType=Active&LCnt rctr=295*1&bc=AggAAAIAlAAAAA%3d%3d&

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

